MGBiotherapeutics - A Genzyme Medtronic joint venture for advancing cardiac care

MG Biotherapeutics Home

Genzyme Corp.

Medtronic, Inc.

		Clinical Trial Overview Learn about the MAGIC phase II clinical trial that has recently discontinued enrollment in Europe.

Developing Novel Therapies

MG Biotherapeutics, LLC - a Medtronic-Genzyme joint venture - is developing novel therapies that combine biologics and delivery devices for the treatment of advanced cardiovascular disease. The company is currently focusing on cellular therapies that can be delivered directly to the heart, to investigate the potential for repairing tissue damaged as a result of a heart attack.

Version 1.2



			DISCLAIMER Please note that the MAGIC (Myoblast Autologous Grafting in Ischemic Cardiomyopathy) phase II clinical trial study being conducted in Europe has recently discontinued enrollment. The study does not involve healthcare professionals or patients in the United States. The information about this clinical trial is therefore intended for healthcare professionals and researchers located outside the United States, its territories and Puerto Rico.